August 19, 2019
Morrisville, N.C. – August 19, 2019 – Q2 Solutions, a leading clinical trial laboratory services organization, announced today the addition of Dr. Bob Bailer as Head of the Vaccines Business Unit.
As Head of the Vaccines Business Unit, Dr. Bailer leads a well-established team focused on lab services to support vaccine immunogenicity and efficacy studies, viral and bacterial neutralization assays across multiple platforms, custom PCR development to support vector-specific detection, immunoassay development in ELISA and Luminex platforms, and expertise in influenza vaccine clinical trials with a full range of lab services.
“We are very excited to have Bob join our team and look forward to his contributions and positive impact to the business”, said Kevin Jones, Q2 Solutions General Manager, Bioanalytical/ADME and Vaccines Laboratories. Bob’s broad and deep knowledge across science, technology, regulatory, and laboratory operations will enable him to execute on our growth strategy and provide leadership and insights for employees and customers."
Dr. Bailer joins us from the National Institute of Health (NIH) where he served as the Director of the Vaccine Immunogenicity Testing Program. Prior to the NIH, Bob held increasing roles of responsibility across pharma and US government agencies. Bob obtained his undergraduate degree in Microbiology from Colorado State University, and his Ph.D. in Viral Immunology from The Ohio State University.
Click here to learn more about Q2 Solutions clinical vaccine laboratory services.
About Q2 Solutions
Q2 Solutions is a leading clinical trial laboratory services organization with end-to-end laboratory services and secure, enterprise-wide biospecimen and consent management solutions. With a relentless focus on quality and innovation, Q2 Solutions uses its global experience and scientific expertise to transform science and data into actionable medical insights that help customers improve human health. A joint venture of IQVIA (formerly QuintilesIMS) and Quest Diagnostics, Q2 Solutions combines the best of each parent organization’s clinical trials laboratory services capabilities to fulfill its mission of treating each sample as if a life depends on it. To learn more, visit www.q2labsolutions.com.
You may also be interested in

August 11, 2025
Luc Gagnon, IQVIA Laboratories’ global head of vaccine sciences, appointed to CEPI’s Global Central Laboratory Network Advisory Council
.
August 11, 2025
IQVIA Laboratories wins Vaccine Industry Excellence Award for Best Central/Specialty Laboratory for second consecutive year
.
March 4, 2025
IQVIA Laboratories Launches Site Lab Navigator with Breakthrough e-Requisition Innovation to Transform Clinical Trials
IQVIA Laboratories launches Site Lab Navigator, an advanced e-Requisition ...
October 9, 2024